Esperion Therapeutics Q2 EPS $(0.46) Beats $(0.63) Estimate, Sales $25.79M Beat $25.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics reported Q2 earnings per share (EPS) of $(0.46), beating the analyst consensus estimate of $(0.63) by 26.98%. This is a 56.19% increase over losses from the same period last year. The company also reported quarterly sales of $25.79 million, beating the analyst consensus estimate of $25.50 million by 1.12%, a 36.86% increase over the same period last year.
August 01, 2023 | 10:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics reported better than expected Q2 earnings and sales, which could positively impact its stock price.
Esperion Therapeutics reported Q2 earnings and sales that beat analyst estimates. This is generally seen as positive news and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100